News | January 01, 2026
Establishment Labs seeks FDA nod for Motiva breast reconstruction implants
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Subscribe To Our Newsletter & Stay Updated
